Analyst: New UK monkeypox strategy might boost Bavarian Nordic orders

The UK plans to offer Bavarian Nordic’s vaccine, Imvanex, to a broader segment of people at risk of exposure. Wider use could lead to more orders from governments, assesses one analyst.
Photo: Dado Ruvic/Reuters/Ritzau Scanpix
Photo: Dado Ruvic/Reuters/Ritzau Scanpix
by marketwire, translated by daniel pedersen

On Tuesday, the UK announced plans to provide Bavarian Nordic’s vaccine, Imvanex, to a wider segment of people at-risk of exposure, including gay and bisexual men. Previously, vaccination was only recommended for those who had been in close contact with someone carrying the infection.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading